Ethnic differences in glycemic markers in patientswith type 2 diabetes

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 2931-2936

  Wolffenbuttel, Bruce H R ^a   Herman, William H ^b   Gross, Jorge L ^c   Dharmalingam, Mala ^d   Jiang, Honghua H ^e   Hardin, Dana S ^e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Centro de Pesquisa Em Diabetes   (Brazil)

^d Bangalore Endocrinology and Diabetes Research Centre   (India)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN LISPRO; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; ASIAN; BLOOD GLUCOSE MONITORING; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISPANIC; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; VERY ELDERLY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED;

EID: 84891839238     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2711     Document Type: Article

References (22)

1. Cerami A. The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's. J Intern Med 2012;271: 219-226
2. Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2008;31:240-246
3. Herman WH, Ma Y, Uwaifo G, et al.; Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30: 2453-2457
4. HermanWH, Dungan KM,Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94: 1689-1694
5. Chalew S, Hempe JM. Caveats regarding the use of HbA1c for prediction of mean blood glucose. Diabetologia 2008;51: 903-904; author reply 905-906
6. Kilpatrick ES, Rigby AS, Atkin SL. Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 2007;53:897-901
7. Bloomgarden ZT, Inzucchi SE, Karnieli E, Le Roith D. The proposed terminology 'A (1c)-derived average glucose' is inherently imprecise and should not be adopted. Diabetologia 2008;51:1111-1114
8. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications 2002;16:313-320
9. Rohlfing C, Wiedmeyer HM, Little R, et al. Biological variation of glycohemoglobin. Clin Chem 2002;48:1116-1118
10. Cohen RM, Snieder H, Lindsell CJ, et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 2006;29:1739-1743
11. Jansen H, Stolk RP, Nolte IM, Kema IP, Wolffenbuttel BH, Snieder H. Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the lifelines cohort study. J Intern Med 2013;273:283-293
12. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; A1c-Derived Average Glucose Study Group. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008; 31:1473-1478
13. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;47:153-163
14. Fahrbach J, Jacober S, Jiang H, Martin S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Tech 2008;2:831-838
15. Wolffenbuttel BH, Sels JP, Menheere PP, Nieuwenhuijzen Kruseman AC. The value of fasting blood glucose and serum fructosamine in the evaluation of metabolic control in NIDDM patients. Diabetes Nutr Metab 1991;4:297-303
16. Tran DV, Cembrowski GS, Higgins TN. Use of 2 years of patient data to estimate intra-laboratory total imprecision of HbA (1c) measured by multiple HPLC analyzers. Clin Biochem 2008;41:177-179
17. Ziemer DC, Kolm P, Weintraub WS, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010;152:770-777
18. Tsugawa Y, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should the hemoglobin A(1c) diagnostic cutoff differ between blacks and whites? A cross-sectional study. Ann Intern Med 2012;157:153-159
19. Grimsby JL, Porneala BC, Vassy JL, et al.; MAGIC Investigators. Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. Adults: the third National Health and Nutrition Examination Survey (NHANES III). BMC Med Genet 2012;13:30
20. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430
21. Wolffenbuttel BHR, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996;347:513-515
22. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 2004; 27:1259-1264